() announced it has appointed pharmaceutical executive Bob Woloschuk to its advisory board.
Bob has more than two decades of executive experience in the pharmaceutical industry and an eye for licensing opportunities, both in Canada and in international markets, the firm said.
READ: Canntab Therapeutics unveils major milestone, with Canada Health approval for its sustained release product
"We are grateful for the opportunity to add someone of Bob's calibre to our advisory board, which already included some of the most impressive names in both capital markets, and cannabis research and development,” said chief executive officer, Jeff Renwick, who is also a director.
Canntab’s advisory board is also made up of researcher Sabrina Ramkellawan, cannabis leader Hamish Sutherland and medical doctor, Dr. Eric Hatashita.
“Bob has a long history of successful business development within the key "Big Pharma" industry players, and has significant experience developing licensing strategies in the pharmaceutical industry,” said Renwick. “We look forward to working with Bob, who we believe adds tremendous value to our advisory board and the company as a whole.”
Shares in Canntab were down 0.92% to C$1.08 on Friday morning.
